|
JP6261500B2
(ja)
|
2011-07-22 |
2018-01-17 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ヌクレアーゼ切断特異性の評価および改善
|
|
AU2012305931B2
(en)
|
2011-09-08 |
2017-09-07 |
Yeda Research And Development Co. Ltd |
Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
SG11201609211VA
(en)
|
2014-03-05 |
2016-12-29 |
Nat Univ Corp Univ Kobe |
Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
|
|
US11390921B2
(en)
|
2014-04-01 |
2022-07-19 |
Adaptive Biotechnologies Corporation |
Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
|
|
RU2763795C2
(ru)
|
2014-04-23 |
2022-01-11 |
Джуно Терапьютикс, Инк. |
Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
|
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
WO2016069282A1
(en)
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
|
US10900034B2
(en)
|
2014-12-03 |
2021-01-26 |
Agilent Technologies, Inc. |
Guide RNA with chemical modifications
|
|
CN113713091A
(zh)
|
2015-02-06 |
2021-11-30 |
新加坡国立大学 |
工程免疫细胞及其用途和生产方法
|
|
KR20260048600A
(ko)
*
|
2015-03-27 |
2026-04-10 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
변형된 t 세포 및 이의 제조 및 사용 방법
|
|
EP3280803B1
(en)
|
2015-04-06 |
2021-05-26 |
The Board of Trustees of the Leland Stanford Junior University |
Chemically modified guide rnas for crispr/cas-mediated gene regulation
|
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
JP7057748B2
(ja)
|
2015-07-16 |
2022-04-20 |
イェダ リサーチ アンド ディベロップメント カンパニー リミテッド |
遺伝子改変された抗第三者中枢性メモリーｔ細胞および免疫療法におけるその使用
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
CN117070468A
(zh)
|
2015-10-05 |
2023-11-17 |
精密生物科学公司 |
包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
|
|
EP3359660B1
(en)
|
2015-10-05 |
2019-12-04 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
|
|
JP7109784B2
(ja)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
遺伝子編集のための進化したＣａｓ９蛋白質
|
|
ES2914623T3
(es)
|
2015-11-27 |
2022-06-14 |
Univ Kobe Nat Univ Corp |
Método para convertir una secuencia genómica de una planta monocotiledónea en la que una base de ácido nucleico en la secuencia de ADN diana se convierte de manera específica y el complejo molecular utilizado en el mismo
|
|
CN108884140B
(zh)
|
2015-12-03 |
2022-10-25 |
朱诺治疗学股份有限公司 |
修饰的嵌合受体及相关组合物和方法
|
|
EA201891338A1
(ru)
|
2015-12-04 |
2018-12-28 |
Новартис Аг |
Композиции и способы для иммуноонкологии
|
|
RU2729116C2
(ru)
|
2015-12-16 |
2020-08-04 |
Гритстоун Онколоджи, Инк. |
Идентификация, производство и применение неоантигенов
|
|
WO2017192536A1
(en)
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
JP2019520394A
(ja)
*
|
2016-07-05 |
2019-07-18 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
癌を処置するためのｃｒｉｓｐｒ／ｃａｓ９ベースの組成物および方法
|
|
CN109844116A
(zh)
|
2016-07-05 |
2019-06-04 |
约翰霍普金斯大学 |
包括使用h1启动子对crispr指导rna的改进的组合物和方法
|
|
CN106191062B
(zh)
*
|
2016-07-18 |
2019-06-14 |
广东华南疫苗股份有限公司 |
一种tcr-/pd-1-双阴性t细胞及其构建方法
|
|
KR102547316B1
(ko)
|
2016-08-03 |
2023-06-23 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
NZ750256A
(en)
|
2016-08-03 |
2026-02-27 |
Dipersio John F |
Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
BR112019002779A2
(pt)
|
2016-08-12 |
2019-05-14 |
Toolgen Incorporated |
elemento imunorregulador manipulado e imunidade alterada por este
|
|
US10576167B2
(en)
*
|
2016-08-17 |
2020-03-03 |
Factor Bioscience Inc. |
Nucleic acid products and methods of administration thereof
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
CN106399375A
(zh)
*
|
2016-08-31 |
2017-02-15 |
南京凯地生物科技有限公司 |
利用CRISPR/Cas9敲除人PD‑1基因构建靶向CD19CAR‑T细胞的方法
|
|
CN106480097A
(zh)
*
|
2016-10-13 |
2017-03-08 |
南京凯地生物科技有限公司 |
利用CRISPR/Cas9技术敲除人PD‑1基因构建可靶向MSLN新型CAR‑T细胞的方法及其应用
|
|
CN110139873A
(zh)
*
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
|
EP3526320A1
(en)
|
2016-10-14 |
2019-08-21 |
President and Fellows of Harvard College |
Aav delivery of nucleobase editors
|
|
JP7181862B2
(ja)
|
2016-10-18 |
2022-12-01 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
腫瘍浸潤リンパ球および治療の方法
|
|
CA3041831A1
(en)
*
|
2016-10-27 |
2018-05-03 |
Intima Bioscience, Inc. |
Viral methods of making genetically modified cells
|
|
EP3535387B1
(en)
|
2016-11-07 |
2022-01-12 |
Genovie AB |
An engineered multi-component system for identification and characterisation of t-cell receptors and t-cell antigens
|
|
CN110023497B
(zh)
|
2016-11-07 |
2021-07-13 |
杰诺维有限公司 |
用于t细胞受体合成和向tcr呈递细胞进行稳定的基因组整合的两部分装置
|
|
ES2984900T3
(es)
*
|
2016-11-07 |
2024-10-31 |
Genovie Ab |
Un sistema multicomponente modificado para la identificación y caracterización de receptores de células T, antígenos de células T y su interacción funcional
|
|
GB201622044D0
(en)
*
|
2016-12-22 |
2017-02-08 |
Ucl Business Plc |
T cell-targeted T cells
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
JP7717439B2
(ja)
|
2017-01-10 |
2025-08-04 |
ザ ジェネラル ホスピタル コーポレイション |
修飾されたｔ細胞及びその使用方法
|
|
US11613574B2
(en)
|
2017-01-10 |
2023-03-28 |
The General Hospital Corporation |
Methods and compositions relating to ex vivo culture and modulation of T cells
|
|
CN110392736A
(zh)
*
|
2017-01-18 |
2019-10-29 |
耶达研究及发展有限公司 |
遗传修饰的反抑细胞及其在免疫治疗中的用途
|
|
JP2020510038A
(ja)
|
2017-03-09 |
2020-04-02 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
がんワクチン
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
SG11201908271WA
(en)
*
|
2017-03-14 |
2019-10-30 |
Juno Therapeutics Inc |
Methods for cryogenic storage
|
|
WO2018175636A2
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
WO2018191490A1
(en)
*
|
2017-04-13 |
2018-10-18 |
The Trustees Of The University Of Pennsylvania |
Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
|
|
CA3062165A1
(en)
*
|
2017-05-04 |
2018-11-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for gene editing in t cells using crispr/cpf1
|
|
JP7235391B2
(ja)
|
2017-05-08 |
2023-03-08 |
ツールゲン インコーポレイテッド |
人工的に操作された免疫細胞
|
|
EP4029943A1
(en)
*
|
2017-05-08 |
2022-07-20 |
Precision Biosciences, Inc. |
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
|
|
MX2019013514A
(es)
*
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
JP2020525537A
(ja)
*
|
2017-06-12 |
2020-08-27 |
エモリー ユニバーシティー |
Ｔ細胞抗原標的キメラ抗原受容体（ｃａｒ）、及び細胞療法での使用
|
|
CA3067382A1
(en)
|
2017-06-15 |
2018-12-20 |
The Regents Of The University Of California |
Targeted non-viral dna insertions
|
|
KR20200018572A
(ko)
*
|
2017-06-20 |
2020-02-19 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
시험관 내에서 Ｔ 세포 내 표적 유전자를 녹아웃시키는 방법 및 그 방법에 이용되는 ｃｒＲＮＡ
|
|
WO2018236909A1
(en)
*
|
2017-06-20 |
2018-12-27 |
La Jolla Institute For Allergy And Immunology |
Engineered t-cell receptors and methods of their use in modulating inflammatory responses and treating atherosclerosis
|
|
CA3068465A1
(en)
|
2017-06-30 |
2019-01-03 |
Precision Biosciences, Inc. |
Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
|
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
|
|
US20190038733A1
(en)
|
2017-08-10 |
2019-02-07 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
|
|
EP3441461A1
(en)
*
|
2017-08-11 |
2019-02-13 |
Baylor College of Medicine |
Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
CN109456943A
(zh)
*
|
2017-09-06 |
2019-03-12 |
亘喜生物科技（上海）有限公司 |
通用型嵌合抗原受体t细胞制备技术
|
|
CN109468278A
(zh)
*
|
2017-09-08 |
2019-03-15 |
科济生物医药（上海）有限公司 |
基因工程化的t细胞及应用
|
|
TW201920661A
(zh)
*
|
2017-09-18 |
2019-06-01 |
大陸商博雅輯因（北京）生物科技有限公司 |
一種基因編輯t細胞及其用途
|
|
WO2019060425A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
COMPOSITIONS FOR CHIMERIC ANTIGENIC RECEPTOR T CELL THERAPY AND USES THEREOF
|
|
CN109517820B
(zh)
*
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
|
CN107630006B
(zh)
*
|
2017-09-30 |
2020-09-11 |
山东兴瑞生物科技有限公司 |
一种制备tcr与hla双基因敲除的t细胞的方法
|
|
BR112020006643A2
(pt)
*
|
2017-10-03 |
2020-09-24 |
Juno Therapeutics Inc |
moléculas de ligação específica ao hpv
|
|
KR20260039788A
(ko)
|
2017-10-10 |
2026-03-20 |
시애틀 프로젝트 코포레이션 |
핫스팟을 이용한 신생항원 동정
|
|
TWI814746B
(zh)
*
|
2017-10-10 |
2023-09-11 |
國立大學法人廣島大學 |
使用鉑talen之t細胞受體之完全置換技術
|
|
WO2019073965A1
(ja)
|
2017-10-10 |
2019-04-18 |
国立大学法人広島大学 |
エフェクターＴ細胞（Ｔｅｆｆ）抗原受容体を用いた抗原特異的制御性Ｔ細胞（Ｔｒｅｇ）の作出技術
|
|
KR20250107288A
(ko)
|
2017-10-16 |
2025-07-11 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
CN107759700A
(zh)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
靶向cd19抗原的转基因t细胞及其制备方法与应用
|
|
CN107759699A
(zh)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
靶向cd30抗原的转基因t细胞及其制备方法与应用
|
|
CN107827989A
(zh)
*
|
2017-10-18 |
2018-03-23 |
银丰生物工程集团有限公司 |
靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用
|
|
CN107723275B
(zh)
*
|
2017-10-20 |
2020-09-04 |
重庆精准生物技术有限公司 |
通用型car-t细胞及其制备方法和应用
|
|
KR102503130B1
(ko)
|
2017-10-27 |
2023-02-24 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
내인성 t 세포 수용체의 표적화된 대체
|
|
MX2020004541A
(es)
|
2017-10-30 |
2021-04-12 |
Pact Pharma Inc |
Edicion de genes de celulas primarias.
|
|
CN107916269B
(zh)
*
|
2017-11-17 |
2020-12-11 |
山东兴瑞生物科技有限公司 |
靶向cd19的tcr基因、制备方法、具有该基因的质粒、试剂盒及应用
|
|
CA3083097A1
(en)
|
2017-11-22 |
2019-05-31 |
Gritstone Oncology, Inc. |
Reducing junction epitope presentation for neoantigens
|
|
WO2019106163A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Cellectis |
Reprogramming of genetically engineered primary immune cells
|
|
WO2019118516A1
(en)
*
|
2017-12-11 |
2019-06-20 |
Editas Medicine, Inc. |
Cpf1-related methods and compositions for gene editing
|
|
WO2019118508A1
(en)
*
|
2017-12-12 |
2019-06-20 |
The Trustees Of The University Of Pennsylvania |
Genetically modified immune cells targeting ny-eso-1 and methods of use thereof
|
|
CN111479917A
(zh)
*
|
2017-12-13 |
2020-07-31 |
詹森生物科技公司 |
经基因修饰以消除T细胞受体和β2-微球蛋白表达的永生化CAR-T细胞
|
|
WO2019118949A1
(en)
|
2017-12-15 |
2019-06-20 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
AU2018396083B2
(en)
*
|
2017-12-29 |
2025-09-25 |
Cellectis |
Method for improving production of CAR T cells
|
|
CN108559760A
(zh)
*
|
2018-01-09 |
2018-09-21 |
陕西师范大学 |
基于CRISPR靶向基因组修饰技术建立荧光素酶knock-in细胞系的方法
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
PT3737765T
(pt)
|
2018-01-12 |
2022-03-11 |
Curocell Inc |
Células imunitárias melhoradas utilizando shrna duplo e composição incluindo as mesmas
|
|
EP3765054A4
(en)
|
2018-01-19 |
2022-01-12 |
The Trustees Of The University Of Pennsylvania |
COMPOSITIONS AND METHODS FOR TARGETING GAMMA DELTA T LYMPHOCYTES USING CHIMERIC ANTIGEN RECEPTORS
|
|
CN108103027B
(zh)
*
|
2018-02-02 |
2021-12-24 |
中国医学科学院血液病医院（血液学研究所） |
高效率血细胞重编程同时实现基因编辑的方法
|
|
CA3090791A1
(en)
*
|
2018-02-11 |
2019-08-15 |
Memorial Sloan-Kettering Cancer Center |
Non-hla restricted t cell receptors and uses thereof
|
|
CN119851752A
(zh)
|
2018-02-27 |
2025-04-18 |
磨石生物公司 |
利用泛等位基因模型进行的新抗原鉴别
|
|
MX2020009272A
(es)
|
2018-03-06 |
2021-01-08 |
Univ Pennsylvania |
Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
|
|
US11447769B2
(en)
|
2018-03-27 |
2022-09-20 |
The Trustees Of The University Of Pennsylvania |
Modified immune cells having enhanced function and methods for screening for same
|
|
SG11202009697RA
(en)
|
2018-03-30 |
2020-10-29 |
Univ Geneve |
Micro rna expression constructs and uses thereof
|
|
SG11202009761YA
(en)
|
2018-04-02 |
2020-10-29 |
Pact Pharma Inc |
Peptide-mhc compacts
|
|
AU2019249209A1
(en)
|
2018-04-05 |
2020-10-15 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
|
CA3094468A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
|
KR20210020873A
(ko)
|
2018-04-05 |
2021-02-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법
|
|
CA3095795A1
(en)
|
2018-04-12 |
2019-10-17 |
Precision Biosciences, Inc. |
Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene
|
|
CN108490174B
(zh)
*
|
2018-04-18 |
2022-06-24 |
上海尚珞生物医药科技有限公司 |
检测car-t细胞的方法及其应用
|
|
US20210077530A1
(en)
*
|
2018-04-26 |
2021-03-18 |
Baylor College Of Medicine |
Auto/allo-immune defense receptors for the selective targeting of activated pathogenic t cells and nk cells
|
|
US12227763B2
(en)
*
|
2018-05-11 |
2025-02-18 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
KR20210045360A
(ko)
|
2018-05-16 |
2021-04-26 |
신테고 코포레이션 |
가이드 rna 설계 및 사용을 위한 방법 및 시스템
|
|
EP3797160A1
(en)
|
2018-05-23 |
2021-03-31 |
The Broad Institute Inc. |
Base editors and uses thereof
|
|
SG11202011383VA
(en)
*
|
2018-05-31 |
2020-12-30 |
Univ Washington |
Chimeric antigen receptor t cells (car-t) for the treatment of cancer
|
|
US20200109364A1
(en)
*
|
2018-05-31 |
2020-04-09 |
Washington University |
Methods for genome-editing and activation of cells
|
|
CN110616188B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种通用型car-t细胞及其制备方法和应用
|
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
WO2020033366A1
(en)
*
|
2018-08-08 |
2020-02-13 |
Nantbio, Inc. |
Recombinant cd1-restricted t cells and methods
|
|
CN110904045A
(zh)
*
|
2018-09-17 |
2020-03-24 |
中国科学院动物研究所 |
经修饰的t细胞、其制备方法及用途
|
|
CA3122131A1
(en)
*
|
2018-09-21 |
2020-03-26 |
Zonghai Li |
Method for gene editing of cell on the basis of crispr/cas system
|
|
EP3868887A4
(en)
*
|
2018-09-25 |
2022-12-07 |
Microbial Chemistry Research Foundation |
NOVEL VIRAL VECTOR AND METHODS OF PRODUCTION AND USE THEREOF
|
|
EP3856763A1
(en)
|
2018-09-28 |
2021-08-04 |
Massachusetts Institute of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
CN109295106B
(zh)
*
|
2018-09-30 |
2020-07-24 |
北京鼎成肽源生物技术有限公司 |
一种hafft1细胞
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
JP2022512703A
(ja)
*
|
2018-10-16 |
2022-02-07 |
インテリア セラピューティクス，インコーポレイテッド |
免疫療法のための組成物および方法
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
CN113015750A
(zh)
|
2018-11-07 |
2021-06-22 |
克里斯珀医疗股份公司 |
抗liv1免疫细胞癌症疗法
|
|
WO2020095248A1
(en)
*
|
2018-11-07 |
2020-05-14 |
Crispr Therapeutics Ag |
Anti-ptk7 immune cell cancer therapy
|
|
SG11202103832SA
(en)
*
|
2018-11-07 |
2021-05-28 |
Crispr Therapeutics Ag |
Anti-cd33 immune cell cancer therapy
|
|
WO2020103013A1
(en)
*
|
2018-11-21 |
2020-05-28 |
Nanjing Bioheng Biotech Co., Ltd |
Modified t cells and uses thereof
|
|
KR102840400B1
(ko)
|
2018-12-12 |
2025-08-04 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 및 car-t 세포 및 사용 방법
|
|
CN109652378B
(zh)
*
|
2018-12-29 |
2020-04-24 |
广州百暨基因科技有限公司 |
一种功能增强的通用型car-t细胞及其制备方法和用途
|
|
CN109722437B
(zh)
*
|
2018-12-29 |
2020-01-07 |
广州百暨基因科技有限公司 |
一种通用型car-t细胞及其制备方法和用途
|
|
US20220133790A1
(en)
*
|
2019-01-16 |
2022-05-05 |
Beam Therapeutics Inc. |
Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance
|
|
EP3911369A4
(en)
|
2019-01-18 |
2022-11-16 |
Orthobio Therapeutics, Inc. |
EDITING GENES TO IMPROVE JOINT FUNCTION
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
IL316576A
(en)
|
2019-02-12 |
2024-12-01 |
Pact Pharma Inc |
Preparations and methods for identifying antigen-specific T cells
|
|
WO2020168122A1
(en)
|
2019-02-13 |
2020-08-20 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
AU2020224681A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
JP7710373B2
(ja)
|
2019-02-21 |
2025-07-18 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
|
|
EP3927847A4
(en)
|
2019-02-22 |
2023-04-19 |
Garvan Institute of Medical Research |
Methods of modulating immune response via snvs of a20 that can "tune" the immune system of a subject
|
|
CN109913501B
(zh)
*
|
2019-03-01 |
2022-08-16 |
华东师范大学 |
一种靶向cd152的复制缺陷性重组慢病毒car-t转基因载体及构建方法
|
|
CN111676195A
(zh)
*
|
2019-03-11 |
2020-09-18 |
北京卡替医疗技术有限公司 |
一种治疗t细胞肿瘤的ucar免疫细胞
|
|
AU2020243431B2
(en)
*
|
2019-03-18 |
2025-12-18 |
Ludwig Institute For Cancer Research Ltd. |
A2/NY-ESO-1 specific T cell receptors and uses thereof
|
|
JP7657726B2
(ja)
|
2019-03-19 |
2025-04-07 |
ザ ブロード インスティテュート，インコーポレーテッド |
編集ヌクレオチド配列を編集するための方法および組成物
|
|
WO2020191378A1
(en)
*
|
2019-03-21 |
2020-09-24 |
Allogene Therapeutics, Inc. |
METHODS FOR ENHANCING TCRαβ+ CELL DEPLETION EFFICIENCY
|
|
JP7286796B2
(ja)
|
2019-04-03 |
2023-06-05 |
プレシジョン バイオサイエンシズ，インク． |
マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
US20220249558A1
(en)
*
|
2019-04-30 |
2022-08-11 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質－金属水酸化物錯体およびその方法
|
|
CN112430575B
(zh)
*
|
2019-08-26 |
2024-01-19 |
深圳市菲鹏生物治疗股份有限公司 |
通用型car-t细胞及其制备方法、应用以及抗肿瘤药物
|
|
US12344656B2
(en)
*
|
2019-09-06 |
2025-07-01 |
Crispr Therapeutics Ag |
Genetically engineered T cells having improved persistence in culture
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
EP4034138A4
(en)
*
|
2019-09-27 |
2024-07-31 |
Beam Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
BR112022009137A2
(pt)
*
|
2019-11-13 |
2022-07-26 |
Crispr Therapeutics Ag |
Métodos de fabricação de células t com receptor de antígeno quimérico (car)
|
|
TW202132333A
(zh)
*
|
2019-11-13 |
2021-09-01 |
瑞士商Ｃｒｉｓｐｒ治療公司 |
製造可表達嵌合抗原受體的ｔ細胞製法
|
|
CN120905142A
(zh)
*
|
2019-11-20 |
2025-11-07 |
卡瑟里克斯私人有限公司 |
用于提供具有增强功能的免疫细胞的方法
|
|
WO2021108557A1
(en)
*
|
2019-11-27 |
2021-06-03 |
Stitch Bio, Llc |
Methods and compositions for inducing tumor cell death
|
|
JP7670358B2
(ja)
*
|
2020-01-02 |
2025-04-30 |
寧波茂行生物医薬科技有限公司 |
修飾された免疫エフェクター細胞及びその調製方法
|
|
CN116234829A
(zh)
|
2020-01-03 |
2023-06-06 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
WO2021147891A1
(zh)
*
|
2020-01-21 |
2021-07-29 |
苏州克睿基因生物科技有限公司 |
一种经修饰的免疫效应细胞及其用途
|
|
US20210254005A1
(en)
*
|
2020-01-23 |
2021-08-19 |
Kangstem Biotech Co., Ltd. |
Off-the-shelf stem cell and immune cell, and a pharmaceutical composition including the same
|
|
CA3174332A1
(en)
|
2020-04-21 |
2021-10-28 |
Jason PERERA |
Tcr/bcr profiling
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
|
CN113684258B
(zh)
|
2020-05-18 |
2024-08-20 |
上海赛比曼生物科技有限公司 |
用于检测鼠源tcr转基因拷贝数的试剂盒及方法
|
|
CA3188143A1
(en)
*
|
2020-06-25 |
2021-12-30 |
The Methodist Hospital |
Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
|
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
WO2022012531A1
(zh)
*
|
2020-07-14 |
2022-01-20 |
苏州克睿基因生物科技有限公司 |
一种经修饰的免疫细胞的制备方法
|
|
WO2022012591A1
(zh)
*
|
2020-07-15 |
2022-01-20 |
南京北恒生物科技有限公司 |
用于同种异体移植的工程化免疫细胞
|
|
IL299846A
(en)
*
|
2020-07-16 |
2023-03-01 |
Orthobio Therapeutics Inc |
Gene editing to improve joint function
|
|
WO2022040454A1
(en)
*
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
|
AU2021347359A1
(en)
|
2020-09-25 |
2023-05-18 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
CN117042780A
(zh)
*
|
2020-10-13 |
2023-11-10 |
宾夕法尼亚大学理事会 |
用于mRNA治疗剂的T细胞的体内靶向
|
|
CN112266899A
(zh)
*
|
2020-10-26 |
2021-01-26 |
北京卡替医疗技术有限公司 |
修饰的免疫细胞及其用途
|
|
WO2022106731A1
(en)
*
|
2020-11-23 |
2022-05-27 |
Ludwig-Maximilians-Universität München |
Cd28-targeting chimeric antigen receptor (car) t cells, methods of generation and uses thereof
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
AU2021392032A1
(en)
|
2020-12-03 |
2023-06-22 |
Century Therapeutics, Inc. |
Genetically engineered cells and uses thereof
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
CN112899227B
(zh)
*
|
2021-01-14 |
2022-09-13 |
中国科学院微生物研究所 |
一种调控辅助性t细胞功能的方法
|
|
JP2024509853A
(ja)
|
2021-03-03 |
2024-03-05 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
|
|
WO2022187663A1
(en)
*
|
2021-03-04 |
2022-09-09 |
Allogene Therapeutics, Inc. |
Fasl expression and fasr gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death
|
|
US20240148791A1
(en)
*
|
2021-03-08 |
2024-05-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for assessing and treating t cell dysfunction
|
|
JP2024534945A
(ja)
|
2021-09-10 |
2024-09-26 |
アジレント・テクノロジーズ・インク |
化学修飾を有するプライム編集のためのガイドｒｎａ
|
|
WO2023055942A1
(en)
*
|
2021-09-29 |
2023-04-06 |
The Johns Hopkins University |
Methods and compositions to augment efficacy and reduce toxicity of non-engrafting, cd8-depleted allogenic donor lymphocyte infusions
|
|
WO2023057285A1
(en)
|
2021-10-06 |
2023-04-13 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
AU2022366987A1
(en)
|
2021-10-14 |
2024-05-16 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed shrnas and logic gate systems
|
|
US20260083848A1
(en)
|
2021-11-03 |
2026-03-26 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
CN113980907B
(zh)
*
|
2021-12-24 |
2022-03-15 |
山东兴瑞生物科技有限公司 |
一种抗flt3嵌合抗原受体修饰的t细胞及其在制备治疗aml药物中的应用
|
|
CN114591963B
(zh)
*
|
2022-05-10 |
2022-07-19 |
上海优替济生生物医药有限公司 |
sgRNA及利用其构建GM-CSF(-)细胞的方法
|
|
CN120152717A
(zh)
|
2022-09-08 |
2025-06-13 |
朱诺治疗学股份有限公司 |
T细胞疗法和连续或间歇dgk抑制剂给药的组合
|
|
IL319698A
(en)
*
|
2022-09-19 |
2025-05-01 |
Emendobio Inc |
Biallelic silencing of PDCD1
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
AU2023390911A1
(en)
*
|
2022-12-09 |
2025-03-27 |
Research Institute At Nationwide Children's Hospital |
Chimeric antigen receptor (car) t cells and uses thereof
|
|
WO2024121426A1
(en)
*
|
2022-12-09 |
2024-06-13 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Method for optimizing t cells for immuno-therapy
|
|
CN121002052A
(zh)
|
2023-02-03 |
2025-11-21 |
C3S2 有限公司 |
用于非病毒生产工程化免疫细胞的方法
|
|
AU2024217219A1
(en)
*
|
2023-02-10 |
2025-09-11 |
Nanjing Bioheng Biotech Co., Ltd |
Function-enhanced cell therapy
|
|
KR20250158048A
(ko)
|
2023-03-03 |
2025-11-05 |
아스널 바이오사이언시스, 인크. |
Psma 및 ca9을 표적으로 하는 시스템
|
|
WO2025082418A1
(zh)
*
|
2023-10-18 |
2025-04-24 |
苏州沙砾生物科技有限公司 |
一种鉴定靶标的方法及其应用
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|